David Scott Miller, Professor and Chief of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, leads the team of gynecologic oncologists at UT Southwestern. He is Medical Director for the Division's practice at the NCI-designated Harold C. Simmons Cancer Center.
Dr. Miller also serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern and participates in the cancer treatment protocols developed by that organization.
A graduate of the University of Oklahoma College of Medicine, Dr. Miller completed his residency in obstetrics and gynecology at the Hospital of the Medical College of Pennsylvania. After residency, he pursued a reproductive endocrinology fellowship at the University of California-San Diego and a gynecologic oncology fellowship at Stanford University Medical Center. Before joining the faculty at UT Southwestern in 1991, he practiced gynecologic oncology at Northwestern University Medical School in Chicago.
Widely-known as an authority on cancers of the female reproductive system, Dr. Miller is board certified in both obstetrics and gynecology and gynecologic oncology. He serves as an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology. He is a member of the Society of Gynecologic Oncologists, American Society of Clinical Oncology, American Congress of Obstetricians and Gynecologists, and the American College of Surgeons.
Dr. Miller believes the gynecologic oncology team’s strength comes from its collaborative approach to health care and commitment to search for the best treatment options for women with cancer of the reproductive system. This approach goes beyond treatment of the cancer itself to include the patient’s nutrition and pain management as well as psychological and social adjustments.
- Medical School
- University of Oklahoma at Tulsa (1977)
- Medical College of Pennsylvania (1978), Obstetrics & Gynecology
- Medical College of Pennsylvania (1981), Obstetrics & Gynecology
- University of California at San Diego (1982), Gynecologic Oncology
- Stanford University Hospital (1985), Gynecologic Oncology
- Antineoplastic drug development
- Clinical trials
- Gynecologic Oncology
- Reconstructive pelvic surgery
- A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
- Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM Gynecol. Oncol. 2012 Dec 127 3 456-61
- Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.
- Boren T, Lea J, Kehoe S, Miller DS, Richardson D Gynecol. Oncol. 2012 Oct 127 1 43-6
- Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?
- Garcia-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS Am. J. Obstet. Gynecol. 2012 Mar 206 3 242.e1-5
- The role of lymphadenectomy in endometrial cancer.
- Kehoe SM, Miller DS Clin Obstet Gynecol 2011 Jun 54 2 235-44
- A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
- Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS Gynecol. Oncol. 2011 Apr 121 1 118-21
- Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
- Boren TP, Miller DS Womens Health (Lond Engl) 2010 Nov 6 6 789-95
- A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
- Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J Int. J. Gynecol. Cancer 2010 Oct 20 7 1137-41
- Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
- Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH Cancer Res. 2009 Dec 69 23 9038-46
- A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
- Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN Gynecol. Oncol. 2009 Dec 115 3 443-6
- Pharmacotherapy of endometrial cancer.
- Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ Expert Opin Pharmacother 2009 Aug 10 12 1939-51
Honors & Awards
- Top Doctor - Gynecologic Oncology / Gynecology
U.S. News and World Report (2013)
- D Best Doctor - Gynecological Oncology
D Magazine - 2012, 2011, 2010 (2010-2012)
- Super Doctors in Texas - Gynecologic Oncology / Obstetrics & Gynecology
Texas Monthly - Super Doctors (2004-2018)
- National Faculty Award
Council on Resident Education in Obstetrics & Gynecology (2000)
- Senior Residents Award for Outstanding Faculty Teacher
Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas (2000)
- First Prize Scientific Paper Award
American College of Obstetricians & Gynecologists, 39th Annual Meeting (1991)
- American College of Obstetricians & Gynecologists
- American College of Surgeons
- American Society of Clinical Oncology
- Gynecologic Oncology Group
- Society of Gynecologic Oncology